Navigation Links
NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Date:4/8/2013

ior manager from big pharma, who has taken blockbuster drugs through development and into commercialization;
  • expansion of the Company's Board with experts in the biotech/pharma sector and in manufacturing; and
  • issuance of a dozen new patents in the Company's worldwide patent portfolio.
  • The Company's cash expenditures of $22.8 million for all of these operations in 2012 were substantially below the level of expenditures usually seen with companies that are in large Phase III clinical trials, and/or that have multiple product development programs under way, especially with operations on two continents.

    The Company's progress has continued to accelerate in 2013.  It differentiates NW Bio as a leader in immune therapies for cancer in multiple ways, including the following:

  • having 3 distinct product lines, with 2 products at the Phase III stage, and the 3rd product in the process of entering an unusually broad combined Phase I/II trial;
  • having 2 products that are each expected to be applicable to all solid tumor cancers (one for cases with tumors that are surgically removed and the other for inoperable tumors);
  • having manufacturing processes for 2 products that have been accepted by regulators for clinical trials at the Phase III level (which processes must be the same as will be used for commercialization) – a significant milestone, especially for cell therapy products;
  • having operations (both clinical and manufacturing) established in both the US and Europe, the 2 largest medical markets in the world;
  • having over 180 issued and pending patents worldwide;
  • having numerous chances to win in the near term, with 3 parallel product programs with ongoing value milestones;
  • having extensive external validations, through regulatory decisions from highly respected regulators in 3 countries (US, UK and Germany), and multiple large marquee partners. '/>"/>

  • SOURCE Northwest Biotherapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient Therapies
    2. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
    3. Susan Cain Will Kick Off 2013 ASAE Annual Meeting & Exposition, Dan Heath is Closing General Session Speaker
    4. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
    5. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
    6. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
    7. NW Bio To Review Its Leadership Position In Immune Therapy At The 25th Annual Roth Conference
    8. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
    9. Archimedes Inc. Renews Annual Marketing Agreement with HealthEconomics.Com
    10. Palatin Technologies To Present At The 25th Annual ROTH Conference
    11. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has ... now comes with a second treatment cup to help prevent ... new cup is thinner on the edges for a softer ... thin and uneven surfaces on the face, neck and décolleté. ... treatment on areas such as the cheeks and neck, or ...
    (Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
    (Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, ... report to their offering. ... photonic integration traces its roots in the latter ... photonic integration went unexplored and unfulfilled for several ...
    (Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
    Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2
    ... Danaher Corporation (NYSE: DHR ) announced today ... approximately 97% of the currently issued shares of Genetix Group ... dated December 18, 2009. , Danaher intends to acquire any ... acquisition provisions of the applicable UK companies legislation. , ...
    ... , TSX Exchange Symbol: RVX , Also ... SAN FRANCISCO, CA and CALGARY, Jan. 11 /PRNewswire-FirstCall/ - ... that Donald J. McCaffrey will be presenting at the ... at the Marines, Memorial Club and Hotel in San ...
    ... , BOSTON, Jan. 11 PAREXEL International ... expectations for the second quarter of Fiscal Year 2010 ended ... ending June 30, 2010. The Company,s updated financial guidance ... business wins and cancellations, revised expectations for the amount and ...
    Cached Biology Technology:Danaher Completes Offer for Genetix Group plc 2Resverlogix Presenting at Biotech Showcase 2PAREXEL Issues Updated Financial And Operational Information 2PAREXEL Issues Updated Financial And Operational Information 3PAREXEL Issues Updated Financial And Operational Information 4PAREXEL Issues Updated Financial And Operational Information 5
    (Date:7/11/2014)... Recent evidence has demonstrated that transplantation of mesenchymal stem ... rat or mouse models of Alzheimer,s disease (AD) and ... cerebral ischemia. Few studies are reported on the therapeutic ... with AD and on the effect on oxidative injury ... Yufang Yan and her team, School of Life Sciences, ...
    (Date:7/11/2014)... proteins that let nerve cells send out electrical signals, ... biological tactic that may offer a new way to ... environmentally responsible way. , Their findingthat naturally occurring ... harmless for a closely related onesuggests that insecticides can ... species like bees. A summary of the research, led ...
    (Date:7/10/2014)... 2014  Aware, Inc. (NASDAQ: AWRE ), ... announced on June 26, 2014 that its Board of ... per share, or approximately $40 million in total.  The ... and a payment date of July 24, 2014.  The ... set an ex-dividend date for this special cash dividend. ...
    Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
    ... only multi drug-resistant forms of the disease but could also ... infection as well. Researchers report their results today at ... which this compound is the lead has a very different ... treat tuberculosis. We have identified no cross resistance with ...
    ... great debate has raged over whether organic compounds and ... meteorite Allan Hills 84001 were processed by living creatures ... been under intense scrutiny ever since. Scientists at the ... fresh look at how material associated with carbonate globules ...
    ... concerns that hamper embryonic stem cell research, but they still ... with which adult stem cells differentiate into mature tissue the ... impossible for researchers to multiply them in the laboratory. And ... difficult to use them for treating disease. , Now, ...
    Cached Biology News:Experimental TB drug effective against resistant and latent mycobacterium tuberculosis 2Relic of life in that Martian meteorite? A fresh look 2Powerful technique for multiplying adult stem cells may aid therapies 2Powerful technique for multiplying adult stem cells may aid therapies 3
    One-step, colorimetric, linear detection range 0.7 mg/dL to 300 mg/dL. Procedure: 10 min....
    Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
    Recombinant Mouse LIGHT/TNFSF14...
    Request Info...
    Biology Products: